Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case–control study

BMC Psychiatry

Jonatan Myrup Staalsø¹  Niels Vidiendal Olsen⁴  Martin Balslev Jorgensen²  Henrik Enghusen Poulsen²  Anders Fink-Jensen²  Jens Lykkesfeldt²  Mia Greisen Soendergaard⁵  Ulla Knorr⁵  Anders Jorgensen³ 

[1]Department of Neuroscience and Pharmacology, Laboratory of Neuropsychiatry, University of Copenhagen, Copenhagen, Denmark

[2]Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[3]Psychiatric Centre Copenhagen, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen, DK-2100, Denmark

[4]Department of Neuroanaesthesia, The Neuroscience Centre, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark

[5]Psychiatric Centre Copenhagen, University Hospital of Copenhagen, Copenhagen, Denmark

关键词: Oxidative stress;    Asymmetric dimethylarginine;    Atypical antipsychotics;    Schizophrenia;   

Others  :  1171041
DOI  :  10.1186/s12888-015-0455-4

 received in 2014-10-23, accepted in 2015-03-23,  发布年份 2015

【 摘 要 】

Background

Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.

Methods

We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.

Results

Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.

Conclusions

Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

【 授权许可】

   
2015 Jorgensen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hennekens CH, Hennekens AR, Hollar D, Casey DE: Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005, 150(6):1115-21.
• [2]Hoang U, Stewart R, Goldacre MJ: Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ 2011, 343:d5422.
• [3]Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB: Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007, 68(6):899-907.
• [4]Crump C, Winkleby MA, Sundquist K, Sundquist J: Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study. Am J Psychiatry 2013, 170(3):324-33. doi:10.1176/appi.ajp.2012.12050599
• [5]Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115(10):1285-95.
• [6]Burghardt K, Grove T, Ellingrod V: Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol 2014, 28(4):349-56. doi:10.1177/0269881113516200. Epub 2013 Dec 17
• [7]Forstermann U, Sessa WC: Nitric oxide synthases: regulation and function. Eur Heart J 2012, 33(7):829-37. 837a-837d
• [8]Sydow K, Munzel T: ADMA and oxidative stress. Atheroscler Suppl 2003, 4(4):41-51.
• [9]Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al.: Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24(9):1682-8.
• [10]Korandji C, Zeller M, Guilland JC, Collin B, Lauzier B, Sicard P, et al.: Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. Atherosclerosis 2011, 214(2):310-5.
• [11]Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006, 38(2):126-36.
• [12]Mohan S, Fung HL: Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine. Int J Mol Sci 2012, 13(6):7521-31.
• [13]Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al.: Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009, 40(9):2959-64.
• [14]Anderssohn M, Rosenberg M, Schwedhelm E, Zugck C, Lutz M, Luneburg N, et al.: The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. J Card Fail 2012, 18(12):904-11.
• [15]Duckelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M: Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007, 27(9):2037-42.
• [16]Loland KH, Bleie O, Borgeraas H, Strand E, Ueland PM, Svardal A, et al.: The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. PLoS One 2013, 8(5):e64774.
• [17]Seljeflot I, Nilsson BB, Westheim AS, Bratseth V, Arnesen H: The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. J Cardiac Failure 2011, 17(2):135-42.
• [18]Das I, Khan NS, Puri BK, Hirsch SR: Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 1996, 215(3):209-11.
• [19]Celik C, Cayci T, Ozdemir B, Akgul EO, Zincir S, Balikci A, et al.: Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia. Psychiatry Res 2011, 190(2–3):177-80.
• [20]Zincir S, Zincir SB, Doruk A, Erdem M, Celik C, Ak M, Garip B, Yukselir C, Karaahmetoglu B: Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: A controlled study. Psychiatry Res 2014, 220(1-2):76-80. doi:10.1016/j.psychres.2014.07.013. Epub 2014 Jul 23
• [21]Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al.: SCAN Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990, 47(6):589-93.
• [22]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-76.
• [23]Cohen S, Williamson G: Perceived stress in a probability sample if the United States. In The social psychology of health: Claremont Symposium on applied social psychology. Sage, Newbury Park, CA; 1988.
• [24]Sanders B, Becker-Lausen E: The measurement of psychological maltreatment: early data on the Child Abuse and Trauma Scale. Child Abuse Negl 1995, 19(3):315-23.
• [25]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006, 21(1):1-6.
• [26]Bergstrom A, Staalso JM, Romner B, Olsen NV: Impaired endothelial function after aneurysmal subarachnoid haemorrhage correlates with arginine:asymmetric dimethylarginine ratio. Br J Anaesth 2014, 112(2):311-8.
• [27]Staalso JM, Bergstrom A, Edsen T, Weikop P, Romner B, Olsen NV: Low plasma arginine:asymmetric dimethyl arginine ratios predict mortality after intracranial aneurysm rupture. Stroke 2013, 44(5):1273-81.
• [28]Henriksen T, Hillestrom PR, Poulsen HE, Weimann A: Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-2′-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandem mass spectrometry. Free Radic Biol Med 2009, 47(5):629-35.
• [29]Evans MD, Olinski R, Loft S, Cooke MS: Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB J 2010, 24(4):1249-60.
• [30]Lykkesfeldt J: Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007, 380(1–2):50-8.
• [31]Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Greisen Soendergaard M, Henriksen T, et al.: Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res 2013, 209(3):417-23.
• [32]Brotman DJ, Golden SH, Wittstein IS: The cardiovascular toll of stress. Lancet 2007, 370(9592):1089-100.
• [33]Batten SV, Aslan M, Maciejewski PK, Mazure CM: Childhood maltreatment as a risk factor for adult cardiovascular disease and depression. J Clin Psychiatry 2004, 65(2):249-54.
• [34]Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull 2013, 39(2):306-18.
• [35]Juonala M, Viikari JS, Alfthan G, Marniemi J, Kahonen M, Taittonen L, et al.: Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007, 116(12):1367-73.
• [36]Atzler D, Schwedhelm E, Nauck M, Ittermann T, Boger RH, Friedrich N: Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania. Clin Chem Lab Med 2014, 52(12):1835-42. doi:10.1515/cclm-2014-0314
• [37]El-Khoury JM, Bunch DR, Reineks E, Jackson R, Steinle R, Wang S: A simple and fast liquid chromatography-tandem mass spectrometry method for measurement of underivatized L-arginine, symmetric dimethylarginine, and asymmetric dimethylarginine and establishment of the reference ranges. Anal Bioanal Chem 2012, 402(2):771-9.
• [38]Luneburg N, Xanthakis V, Schwedhelm E, Sullivan LM, Maas R, Anderssohn M, et al.: Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort. J Nutr 2011, 141(12):2186-90.